Synta has signed a deal with Roche to develop and commercialize their oral small-molecule inhibitors of calcium-release-activated calcium (CRAC) channels, for the treatment of rheumatoid arthritis ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback